DUET BIOSYSTEMS, INC

Biotech · Private

AI-powered algorithm and toolkit for discovering and optimizing drug combination therapies by analyzing synergy data across laboratory and clinical datasets

Grants
$285K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
1 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: New Paradigm for Combination Drug Optimization and Discovery$284,736
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2495Cirrus Therapeutics, Inc.—$6.7M
2496Semnur Pharmaceuticals, Inc.—$6.0M
2497b3 bio, inc.—$5.7M
2498DUET BIOSYSTEMS, INC——
2499Trex Bio——
2500Emergent BioSolutions—$48M
2501ARTELO BIOSCIENCES, INC.—$33M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 3
  • Methods For Evaluating Therapeutic Benefit Of Combination Therapiesgranted
  • Therapeutic Methods And Compositions For Treating Cancer Using Braf And/or Mek Inhibitor Combination Therapyapplication
  • Therapeutic Methods And Compositions For Treating Cancer Using Braf And/or Mek Inhibitor Combination Therapyapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.